XHKG
2268
Market cap4.53bUSD
Apr 09, Last price
29.25HKD
1D
1.39%
1Q
-6.10%
IPO
4.46%
Name
WuXi XDC Cayman Inc
Chart & Performance
P/E
116.84
P/S
15.60
EPS
0.24
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2.12b
+114.44%
Net income
284m
+82.07%
CFO
333m
+32.18%
Earnings
Aug 20, 2025
Profile
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 2,123,839 114.44% | 990,423 218.33% | ||
Cost of revenue | 1,780,334 | 821,161 | ||
Unusual Expense (Income) | ||||
NOPBT | 343,505 | 169,262 | ||
NOPBT Margin | 16.17% | 17.09% | ||
Operating Taxes | 76,074 | 40,070 | ||
Tax Rate | 22.15% | 23.67% | ||
NOPAT | 267,431 | 129,192 | ||
Net income | 283,538 82.07% | 155,731 183.51% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 3,603,962 | 1,285,462 | ||
BB yield | ||||
| Debt | ||||
Debt current | 1,247 | 75,557 | ||
Long-term debt | 4,437 | 7,667 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (4,041,899) | (651,748) | ||
| Cash flow | ||||
Cash from operating activities | 332,845 | 251,816 | ||
CAPEX | (529,360) | (387,556) | ||
Cash from investing activities | (91,233) | (1,279,543) | ||
Cash from financing activities | 3,522,104 | 1,328,213 | ||
FCF | (317,603) | (980,033) | ||
| Balance | ||||
Cash | 4,047,583 | 734,972 | ||
Long term investments | ||||
Excess cash | 3,941,391 | 685,451 | ||
Stockholders' equity | 564,052 | 169,518 | ||
Invested Capital | 4,893,106 | 1,375,717 | ||
ROIC | 8.53% | 18.47% | ||
ROCE | 6.29% | 10.95% | ||
| EV | ||||
Common stock shares outstanding | 1,077,970 | 1,178,446 | ||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | 403,018 | 200,074 | ||
EV/EBITDA | ||||
Interest | 742 | 2,916 | ||
Interest/NOPBT | 0.22% | 1.72% | ||